The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Infections Drop As study Backs Long AstraZeneca Jab Dose Interval

Fri, 19th Feb 2021 16:44

(Alliance News) - Coronavirus infections are dropping across the UK, new data suggests, as a study found that giving doses of the Oxford/AstraZeneca PLC vaccine 12 weeks apart improves protection.

Around one in 115 people in private households in England had Covid-19 between February 6 and 12, the Office for National Statistics (ONS) said, down from around one in 80 people from January 31 to February 6.

Meanwhile, in Wales, around one in 125 people are estimated to have had Covid-19 between February 6 and 12, down from one in 85 previously.

In Northern Ireland, the figure is around one in 105 people, down from one in 75, while in Scotland it is around one in 180 people, down from one in 150.

The data, which does not cover care homes and hospitals, is based on swab tests from thousands of people regardless of whether or not they have symptoms.

It comes as new analysis from Oxford University published in The Lancet confirmed that a single dose of the AstraZeneca vaccine offers 76% protection against Covid-19 from 22 days after vaccination, and that this had not waned by the three-month mark.

The UK policy of leaving up to 12 weeks between doses also resulted in a higher efficacy overall, the study found.

There was 81% protection when three months was left between the two doses, compared to 55% for up to a six-week interval.

The Oxford team is still urging people to have two doses of the vaccine because they say it is not yet clear how long protection with a single dose may last.

Meanwhile, government scientists put the R – the number of people an infected person will pass coronavirus on to – at 0.6 to 0.9 for the UK, compared to 0.7 to 0.9 in the previous week.

The lower end estimate is at its lowest point recorded by the scientists, and the R is below 1 in all regions of England.

However, the experts warned that "prevalence of the virus remains high, so it remains vital that everyone continues to stay at home in order to keep the R value down".

Earlier, top scientific advisers said vaccines were having an impact on the pandemic, as Prime Minister Boris Johnson prepares to publish his road map out of lockdown on Monday.

Professor Adam Finn, from the University of Bristol and a member of the Joint Committee on Vaccination and Immunisation (JCVI), said "everything's moving in the right direction" when it comes to how jabs are working.

He told BBC Radio 4's Today programme: "We've now got to the point with the study we're doing in Bristol where we can say with certainty that there is definitely an effect.

"It's just hard to put an exact number on it at this point because… the numbers of cases coming through are still building up, the number of people who've been vaccinated are still going up, but it's becoming clearer for the Pfizer Inc vaccine, which we've been using for a month longer, since early December, and it'll take slightly longer for us to get a firm handle on just how well the AstraZeneca vaccine is preventing hospitalisations too, but they're definitely doing the job."

Professor Neil Ferguson, from Imperial College London, said the data on vaccine effectiveness and how quickly infection, deaths and hospital cases were declining across the country was looking promising.

He said he thought the current lockdown should be lifted in stages, adding: "I am encouraged by the cautious approach being taken, an incremental approach which I think will be adopted, namely relax one thing and see what the impact is, relax again.

"And it still may well be that by the end of May, we're in a very different country than we are today."

Figures show a continued decline since Christmas in the number of new cases of coronavirus, although rates vary according to region.

Overall, 74,961 new cases were recorded in England in the seven days to February 14, the equivalent of 133.2 per 100,000 people.

This is down sharply from a peak of 680.8 cases per 100,000 people on January 4.

It is also the lowest seven-day rate since October 4.

Meanwhile, the number of patients in hospital in England with Covid-19 has also fallen sharply in recent weeks.

A total of 15,633 patients were in hospital as of 8am on February 18, down 54% from a record 34,336 patients exactly one month earlier.

But while this is a sizeable drop, numbers at both a national and regional level are still higher than when England came out of its second lockdown on December 2.

All regions also continue to report patient numbers well above those seen last May, when Boris Johnson announced the initial easing of the first lockdown.

Meanwhile the number of daily hospital admissions of patients with Covid-19 stood at 1,311 on February 16, down 68% from a peak of 4,134 on January 12, but still above the 1,262 on the day England came out of its second lockdown on December 2.

Elsewhere, Wales' First Minister Mark Drakeford has said some aspects of non-essential retail, as well as personal services such as hairdressing, could begin to reopen there from March 15, with stay-at-home restrictions eased in three weeks.

All primary school children in Wales are expected to return to face-to-face teaching from mid-March, while the number of people allowed to exercise together will increase from two to four.

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.